ForTra gGmbH für Forschungstransfer der Else Kröner-Fresenius-Stiftung (ForTra), supports the legally compliant production of new pharmaceutical products under GMP conditions that will be directly used in clinical first-in-human gene and cell therapy trials.

In August 2022 ForTra announced three million euros to be awarded in its call for proposals. Following extensive scientific review and appraisal, five projects were approved and are being funded. The press release dated June 16, 2025 can be found here.

Due to the extraordinarily positive response, a renewed call for proposals was carried out at the end of 2024. Within the scope of this call for proposals, ForTra supports six projects for GMP production of clinical trial material with funding totaling 4.7 million euros. The press release dated June 20, 2023 can be found here.

The applications from the third round of calls for proposals are currently under review. The entire production process or individual parts thereof shall be funded for a variety of gene and cell therapeutics. Up to four million euros will be provided for the whole call for proposals. You can find more information about the call for proposals here.